Cannabis Science (CBIS) 10-Q 9 Jun 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 04, 2016
Document And Entity Information
Entity Registrant Name	CANNABIS SCIENCE, INC.
Entity Central Index Key	1,024,626
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,835,805,296
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets
Cash	$ 15,192	$ 61,971
Other receivables	56,314	39,366
Loans receivable, related party	22,516	37,516
Inventory	84,267	19,311
Prepaid expenses and deposits	162,838	156,750
Total current assets	341,127	$ 314,914
Property farming license (Note 7)	25,000
Deposits (Note 8)	1,152,850	$ 971,500
Equity method investee (Note 9)	198,362	128,927
Goodwill (Note 10)	162,154	170,689
Intangibles, net of accumulated amortization (Note 10)	204,250	215,000
TOTAL ASSETS	2,083,743	1,801,030
Current Liabilities
Accounts payable	747,381	680,215
Accrued expenses, primarily management fees (Note 4)	1,933,654	1,614,654
Advances from related parties (Note 4)	422,080	414,135
Management bonuses	300,000	300,000
Notes payable to stockholders (Note 5)	1,360,658	1,406,513
Total current liabilities and total liabilities	4,763,773	4,415,517
Stockholders' Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at March 31, 2016 and December 31, 2015	1,000	1,000
Common stock, $.001 par value, 3,000,000,000 shares authorized, 1,843,855,296 issued and outstanding as of March 31, 2016 and 1,581,855,296 at December 31, 2015 Common stock, Class A, $.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of March 31, 2016 and December 31, 2015	1,843,856	1,581,856
Prepaid consulting	2,641,794	3,209,032
Common Stock receivable	1,090,000	381,500
Additional paid-in capital	131,089,023	127,942,191
Accumulated deficit	(131,308,104)	(128,017,132)
Cumulative exchange translation	(20,592)	(18,496)
Equity attributable to common shareholders	(2,126,611)	(2,101,113)
Non-Controlling interest	(553,419)	(513,374)
Total stockholders' deficit	(2,680,030)	(2,614,487)
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	2,083,743	1,801,030
Series A Preferred Stock [Member]
Stockholders' Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at March 31, 2016 and December 31, 2015	1,000	1,000
Equity attributable to common shareholders	1,000	1,000
Total stockholders' deficit	1,000	1,000
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	$ 1,000	$ 1,000
Common Class A [Member]
Stockholders' Deficit
Common stock, $.001 par value, 3,000,000,000 shares authorized, 1,843,855,296 issued and outstanding as of March 31, 2016 and 1,581,855,296 at December 31, 2015 Common stock, Class A, $.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of March 31, 2016 and December 31, 2015
Equity attributable to common shareholders
Total stockholders' deficit
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,843,855,296	1,581,855,296
Common stock, shares outstanding	1,843,855,296	1,581,855,296
Series A Preferred Stock [Member]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common Class A [Member]
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated Statements Of Oper

Consolidated Statements Of Operations And Other Comprehensive (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue	$ 2,925
Cost of Goods Sold	1,598
Operating Expenses
Investor relations	157,000	$ 5,000
Professional fees	81,690	25,040
Net loss on settlement of liabilites	(588,645)	$ (2,358,076)
Depreciation and amortization	19,285
Research and development	163,000	$ 197,336
General and administrative	2,391,689	1,651,092
Total operating expenses	3,401,309	4,236,544
Net Operating Loss	(3,399,982)	(4,236,544)
Other Income (Expense)
Interest expense, net	$ 35	280
Impairment of goodwill		64,421
Unrealized gain (loss) on equity investee	$ 69,000	(48,750)
Total other income (expense)	68,965	(113,451)
Net Loss	(3,331,017)	(4,349,995)
Net Loss attributable to non-controlling interest	(40,045)	(8,525)
Net Loss attributable to common shareholders	(3,290,972)	(4,341,470)
Other Comprehensive Income
Foreign exchange translation adjustment	(2,096)	(31,306)
Total other comprehensive income	(2,096)	(31,306)
Net Comprehensive Loss	$ (3,293,068)	$ (4,372,776)
Net loss per common share - Basic and diluted	$ 0	$ 0
Weighted average number of common shares outstanding	1,680,393,758	1,052,605,692

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,331,017)	$ (4,349,995)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,285
Stock issued for services	$ 1,738,220	$ 1,713,671
Stock issued for debt extension
Stock options issued for services	$ 437,000
Loss/ (Gain) on equity investee	$ 69,000	$ (48,750)
Gain on marketable securities
(Gain)/Loss on settlement of liability
Loss on settlement of debt	$ (588,645)	$ (2,358,076)
Impairment loss on goodwill
Warrant expense
Foreign exchange transalation adjustment	$ (2,096)	$ (31,306)
Changes in operating assets and liabilities:
Other receivables	16,948	$ (974)
Equity investee	435
Inventory	64,956
Prepaid expenses and deposits	6,088	$ 43,162
Accounts payable	67,166	97,815
Accrued expenses, primarily management fees	319,000	(118,500)
Loan receivable, related parties	(22,945)	(50,000)
NET CASH USED IN OPERATING ACTIVITES	$ (298,279)	$ (273,677)
CASH FLOWS FROM INVESTING ACTIVITIES
Advances receivable, related parties
Repayment from advances receivable, related party
Property license for cultivation	$ 25,000
CASH FLOWS USED IN INVESTING ACTIVITIES	$ (25,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances from officers
Proceeds from notes payable to stockholders
Repayments of notes payable to stockholders
Advances from related parties		$ 51,140
Proceeds from common stock options exercised	$ 276,500
Proceeds from sale of common stock		$ 250,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	$ 276,500	301,140
NET INCREASE (DECREASE) IN CASH	(46,779)	27,463
CASH, BEGINNING OF PERIOD	61,971	10,061
CASH, END OF PERIOD	15,192	37,524
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services	1,170,982	5,541,037
Common stock issued for settlement of debt	634,500	2,538,904
Debt converted into common stock	$ 45,855	$ 180,828
Common stock issued for assets
Common stock issued for debt extension
Common stock issued for options exercised	$ 1,338,050
Equity investment in Endocan Corporation
Accounts payable paid through note payable, stockholder

Consolidated Statement Of Stock

Consolidated Statement Of Stockholders' Deficit (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Common Shares	Preferred Shares	Additional Paid-In Capital	Prepaid Consulting	Common Stock Receivable	Accumulated Deficit	Foreign Exchange Translation	Non-Controlling Interest	Total
Balance common stock, shares at Dec. 31, 2015	1,581,855,296								1,581,855,296
Balance Preferred stock, shares at Dec. 31, 2015		1,000,000							1,000,000
Balance, value at Dec. 31, 2015	$ 1,581,856	$ 1,000	$ 127,942,191	$ (3,209,032)	$ (381,500)	$ (128,017,132)	$ (18,496)	$ (513,374)	$ (2,614,487)
Common stock issued for services, shares	103,000,000
Common stock issued for services, value	$ 103,000		1,067,982	$ 395,614					775,368
Common stock issued for settlement of liabilities and debt, shares	45,000,000
Common stock issued for settlement of liabilities and debt, value	$ 45,000		$ 589,500						$ 634,500
Common stock issued for private placement, shares
Common stock issued for private placement, value
Common stock issued for deposit to acquire assets, shares	15,500,000
Common stock issued for deposit to acquire assets, value	$ 15,500		$ 165,850						$ 181,350
Common stock issued for stock option exercised, shares	98,500,000								98,500,000
Common stock issued for stock option exercised, value	$ 98,500		1,239,550		$ (708,500)				$ 629,550
Fair Value on option shares not exercised			$ 83,950						83,950
Amortization of shares issued for services				$ 962,852					962,852
Net loss for the period						$ (3,290,972)		$ (40,045)	(3,331,017)
Foreign exchange translation							$ (2,096)		$ (2,096)
Balance Common stock, shares at Mar. 31, 2016	1,843,855,296								1,843,855,296
Balance Preferred stock, shares at Mar. 31, 2016		1,000,000							1,000,000
Balance, amount at Mar. 31, 2016	$ 1,843,856	$ 1,000	$ 131,089,023	$ (2,641,794)	$ (1,090,000)	$ (131,308,104)	$ (20,592)	$ (553,419)	$ (2,680,030)

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. Organization and General Description of Business Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS. Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 th th On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders. On November 20, 2014, the Company signed an amendment to the license agreement with Apothecary Genetics Investments LLC. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary. The Company anticipated closing the purchase in fiscal 2015 once all assets are identified with supported fair market values and the transfer of land title is completed. B. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31. Interim Financial Reporting While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2015 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended March 31, 2016 and 2015. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2015 included in our Form 10-K filed with the SEC on file no. 000-28911 161631274 May 9, 2016. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016. The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the three months ended March 31, 2016: In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany. On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV and MJR BV, both Netherlands registered companies. On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT. On May 6, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. In the state of Tennessee and start the operation of distributing of existing and new line of products. For other accounting policies please refer to the Company’s Form 10-K with the SEC on file no. 000-28911 161631274 May 9, 2016. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have much amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2016
Going Concern
Going Concern	2. GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of $131,308,104 and had a stockholders’ deficit of $2,680,030 as at March 31, 2016. In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At March 31, 2016, the Company had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We anticipate that we will have to raise additional capital to fund operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings. Any future financing may involve substantial dilution to existing investors. We had been relying on our common stock to pay third parties for services which has resulted substantial dilution to existing investors.

Fair Value Measurements And Dis

Fair Value Measurements And Disclosures	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Disclosures	3. FAIR VALUE MEASUREMENTS AND DISCLOSURES ASC Topic 820, Fair Value Measurement

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	4. RELATED PARTY TRANSACTIONS At March 31, 2016, a total of $52,500 (December 31, 2015: $52,500) in loans payable was due to the Company’s CFO, Robert Kane, through his company, R Kane Holding Inc., secured by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt. At March 31, 2016, the Company owes $6,000 (December 31, 2015: $6,000) to R Kane Holding Inc., which advanced a total of $6,000 to Dean Law Trust for payment of the Company’s expenses in July and August of 2015 with no interest and no security. Loan Payable to R Kane Holding Inc., a company controlled by Mr. Robert Kane, director and CFO totaled $58,500 and $0 at March 31, 2016 and 2015 respectively. At March 31, 2016, the Company owes $61,902.15 (December 31, 2015: $61,902.15) to Interstate 101, a shareholder of the Company, with no interest and no security. At March 31, 2016, the Company owes $3,164.72 (December 31, 2015: $3,164.72) to Castor Management Services, a shareholder of the Company, with no interest and no security. At March 31, 2016, a total of $191,344 (December 31, 2015: $191,344) in loans payable was due to Bogat Family Trust, Raymond Dabney the Company’s Director and President/CEO as trustee. At March 31, 2016, $74,792 (December 31, 2015: $66,847) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries. At March 31, 2016, $447 (December 31, 2015: $447) was due to Robert Melamede, former CEO. At March 31, 2016, the Company held 7,500,000 common shares in the Endocan Corporation (formerly X-Change Corporation) (OTCBB: ENDO) (“Endocan”) representing approximately 8.6% of the issued and outstanding shares of Endocan, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0.03 on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of $262,250 or $0.1049 per share on February 8, 2013. The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the Dupetit Natural Products GmbH joint-venture operating agreement to Endocan under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Endocan under an Asset Purchase Agreement. The value of the shares at March 31, 2016 and December 31, 2015 was determined to be $0.015 per share or $112,500 with the Company recording an unrealized gain on equity investee of $69,000 for the three months ended March 31, 2016 and $0.0145 per share or $108,750 with the Company recording an unrealized loss of $48,750 for the three months ended March 31, 2015. On November 5, 2014, the Company transitioned to equity method investee account for the Endocan shares pursuant to ASC 323 recording $247,500 as the fair value of the shares to its equity method investee account. On December 31, 2015, the Company recorded an impairment on the equity method investee account of $114,000 in relation to the shares. Robert Kane, CFO and director of the Company is also the CFO and a director of Endocan. Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Endocan. Raymond Dabney, CEO is the controlling shareholder of Endocan Corporation. For the three months ended March 31, 2016, the following related party stock-based compensation was recorded: Related Party Position Amount Raymond Dabney 1 CEO $ 193,842 Dr. Allen Herman Chief Medical Officer 25,500 Dr. Roscoe M. Moore, Jr Chair of Scientific Advisory Board 151,000 Robert Kane CFO 215,380 Chad S. Johnson, Esq. COO and General Counsel 215,380 Mario Lap 1 Director 215,380 $ 1,016,482 1 Raymond Dabney, CEO is a controlling shareholder and Chad S. Johnson, COO/General Legal Counsel of ImmunoClin Corporation (OTC: IMCL), respectively. ImmunoClin performs laboratory services, research and pharmaceutical development for the Company through its wholly-owned subsidiary ImmunoClin Limited that operates a laboratory at the London Biosciences Centre. See Note 6 -Equity Transactions for details of stock issuances to director and officers for services rendered. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MJR BV and MLS Lap BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. The Company anticipates having the Spanish subsidiary setup in fiscal 2016 at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company. Alfredo Dupetit-Bernardi, International Product Development and President & CEO of Cannabis Science Europe GmbH, is conducting product development through the purchase of cannabis products from his personal company, Dupetit Natural Products GmbH. Notes payable to Embella Holdings Ltd. totaled $1,108,896 and $1,108,896 at March 31, 2016 and 2015, respectively. As of March 31, 2016, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. Notes payable to Intrinsic Capital Corp. totaled $231,260 and $302,088 at March 31, 2016 and 2015, respectively. See Note 5. Between January 1, 2015 to March 7, 2015, R. Kane Holding Inc., a company owned by Mr. Robert Kane, director and CFO, had advanced $52,500 into Michigan Green Technologies, LLC, which is 50.1% controlled by the Company as Loan Payable to R. Kane Holding Inc. On July 25, 2014, Bogat Family Trust, Raymond Dabney trustee, representing a majority of Series A preferred stockholders, signed a resolution to approve an amendment to the certificate of designation preferences and rights for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters. No common stockholders voted on this amendment.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	5. NOTES PAYABLE As of March 31, 2016, a total of $1,360,658 (December 31, 2015: $1,406,513) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through February 7, 2014. The Promissory notes were in default on March 31, 2016. All promissory notes are unsecured. As of March 31, 2016, $61,902 (December 31, 2015: $61,902) of loan payable is due to a stockholder, Interstate 101 that is non-interest bearing is due on demand. The loan originated between April 1, 2015 and December 31, 2015 for various expenses of the Company. As of March 31, 2016, $3,165 (December 31, 2015: $3,165) of loan payable is due to a stockholder, Castor Management Services that is non-interest bearing and is due on demand. The loan originated on August 14, 2015 for expenses of the Company. As of February 7, 2016, the Company has settled the balance of $45,855 promissory note owed to Stacey R. Lewis since March 21, 2015 and issued 45,000,000 shares of common stock pursuant to a debt settlement agreement with a fair market value of $634,500.

Equity Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Equity Transactions	6. EQUITY TRANSACTIONS The Company is authorized to issue 3,000,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 1,843,855,296 and 1,581,855,296 issued and outstanding as of March 31, 2016 and December 31, 2015, respectively. The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share. These shares have 10 votes per share. There were 0 issued and outstanding as of March 31, 2016 and December 31, 2015. The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State. There were 1,000,000 issued and outstanding as of March 31, 2016 and December 31, 2015. As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933. During the three months ended March 31, 2016, the Company issued 103,000,000 common stock for services under various executive and consulting agreements as follows: On February 1, 2016, the Company entered a management agreement with a consulting firm and agreed to issue 15,000,000 shares of R144 restricted common stock with a fair market value of $180,000 for investor relation services. The shares were issued on April 7, 2016. On March 8, 2016, the Company issued 18,000,000 shares R144 restricted common stock to Raymond Dabney, CEO of the Company with a fair market value of $193,842 for bonus under November 5, 2014 management agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to MLS Lap BV, a company controlled a director of the Company with a fair market value of $215,380 for bonus under June 24, 2013 management agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, COO/General Council with a fair market value of $215,380 for bonus and services under November 25, 2014 agreement. On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Robert Kane, CFO/director of the Company with a fair market value of $215,380 for bonus and services under January 20, 2015 agreement. On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of $151,000. During the three months ended March 31, 2016, the Company issued stock pursuant to debt settlement agreements as follows: On February 7, 2016, the Company entered into a partial debt settlement agreement with Stacey R. Lewis to retire $45,855 of the $75,044 in promissory notes originated on March 21, 2015 and issued 45,000,000 shares of common stock to partially settle the debt for a loss on settlement of $588,645. The aforementioned shares for the settlement of debts were issued without legend under an exemption under Rule 144(b)(1) of the Act. Over six months has passed since the debts accrued on the books of the Company; the Seller is not now, and during the three-month period preceding the transaction has not been considered an “affiliate” of the Company. Furthermore, pursuant to Rule 144(d)(1)(i) the Company is, and has been for a period of at least 90 days immediately before the proposed sale, subject to the reporting requirements of section 13 or 15(d) of the Securities and Exchange Act of 1934, and the proposed resale of the Shares in addition to the Company not being considered a shell company under Rule 144(i)(1). All relating shares were issued to settle the debts. During the three months ended March 31, 2016, the Company issued stock pursuant to amendment to a property license agreement as follow: On January 11, 2016, the Company issued 15,500,000 shares of R144 restricted common stock to Apothecary Genetics Investments with a fair market value of $181,350 for amendment to a property license agreement on February 9, 2012. Stock Options : The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement: (i) the option to purchase 100,000 common shares at ten cents ($0.10) per share; (ii) the option to purchase 100,000 common shares at twenty cents ($0.20) per share; (iii) the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and (iv) the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share. On February 22, 2016, the Company issued 7,000,000 shares S-8 registered free-trading common stock exercised under Option Agreement of the 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $86,100 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500. On February 22, 2016, the Company issued 6,500,000 shares S-8 registered free-trading common stock exercised under Option Agreement of 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $79,950 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500. On February 29, 2016, the Company issued 25,000,000 shares S-8 registered free--trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $300,000 to a consultant under management agreement. On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at $0.01 and a fair market value of $226,500 to a consultant under management agreement. On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $75,500 to a consultant under management agreement. On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $151,000 to a consultant under management agreement. On March 22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Plan with exercise price at $0.01 and a fair market value of $226,500 to a consultant under management agreement. On March 22, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Scientific Advisory Board Agreement of the 2016 Equity Plan with a fair market value of $151,000. On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $75,500. A summary of the status of the Company’s option grants as of March 31, 2016 and the changes during the period then ended is presented below: Shares Weighted-Average Outstanding December 31, 2015 4,200,000 $ 0.195 Granted 135,000,000 $ 0.010 Exercised 98,500,000 $ 0.010 Expired 2,500,000 $ 0.040 Outstanding March 31, 2016 38,200,000 $ 0.028 Options exercisable at March 31, 2016 38,200,000 $ 0.028 1,700,00 shares of these options at an exercise price of $0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane and 36,500,000 shares at an exercise price of $0.01 a share expires on February 22, 2017. The weighted average fair value at date of grant for options during year ended March 31, 2016 was estimated using the Black-Scholes option valuation model with the following: Average expected life in years for options with no expiry 2 Years Average expected life in years for options with expiry on 02/22/2017 0.8962 Year Average risk-free interest rate 2.00 % Average volatility 90 % Dividend yield 0 %

Property Farming License

Property Farming License	3 Months Ended
	Mar. 31, 2016
Property Farming License
Property Farming License	7. PROPERTY FARMING LICENSE On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made an initial payment of $25,000 for licensing and initial development of the first one (1) acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

Deposits

Deposits	3 Months Ended
	Mar. 31, 2016
Deposits
Deposits	8. DEPOSITS On February 9, 2012, the Company signed a license agreement with Apothecary to produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding in addition to investing $250,000 in research and development in the first 24 months. Apothecary failed to meet several contract provisions including investing $250,000 in R&D, setting up a laboratory facility, and reporting and remitting license fees owing to the Company. On November 20, 2014, the Company signed an amendment to the license agreement. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary in exchange for 14,500,000 Rule 144 restricted stock with a fair market value of $971,500. On January 11 2016, the Company signed a second amendment to the license agreement and issued 15,500,000 shares of Rule 144 restricted stock, held in escrow by the Company’s attorney, with a fair market value of $181,350, until the title has been transferred to the company. Pursuant to the second amendment the Company waives prior Royalties owed under any Section of any previous Agreements, and Apothecary shall make business introductions in Jamaica for the Company to work with government licensed growers, laboratories, doctors, and any other mutually agreeable business introductions. Apothecary will immediately sign and transfer ownership of the Northern California Property to the Company and repay and discharge a lien on the property within 12 months signing the second amendment. The Company recorded an equivalent deposit of $181,350 for the three months ended March 31, 2016 until the acquisition of assets closes, which is anticipated during the second quarter of 2016.

Equity Method Investee

Equity Method Investee	3 Months Ended
	Mar. 31, 2016
Equity Method Investee
Equity Method Investee	9. EQUITY METHOD INVESTEE On November 5, 2014, the Company accounted for its investment and loans in OmniCanna Health Solutions, Inc. (formerly Endocan Corporation) using the equity method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures. In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity’s operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent. The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. Dabney being a controlling shareholder of the Company since September 2009 and a controlling shareholder of OmniCanna Health Solutions, Inc. since June 2013. Therefore, the Company was deemed to have significant influence and control of OmniCanna Health Solutions Inc. On November 5, 2014, the Company recorded $247,500 in marketable securities and $85,862 (based on currency converted as of March 31, 2016) in loans to OmniCanna Health Solutions, Inc. (hereinafter referred as “OHS”) to its equity method investee account in accordance with ASC 323. An unrealized gain on equity investee account of $69,000 was recognized for the three months ended March 31, 2016 and an impairment on the equity method investee account of $48,750 was recognized for the three months ended March 31, 2015 due to the fluctuation in the value of OHS’s marketable securities.

Goodwill And Intangible Assets

Goodwill And Intangible Assets	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Goodwill and Intangible Assets	10. GOODWILL and INTANGIBLE ASSETS March 31, 2016 December 31, 2015 Intellectual assets, primarily intellectual property and goodwill $ 830,988 $ 830,988 Less accumulated amortization (464,584 ) (445,299 ) Total intangible assets, net $ 366,404 $ 385,689 Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for both intellectual assets and Goodwill).

Commitments

Commitments	3 Months Ended
	Mar. 31, 2016
Commitments
Commitments	11. COMMITMENTS The Company has lease commitments for its European operations under private companies, MLS Lap B.V. and MJR B.V. owned and controlled by Mario Lap, director of the Company and director and officer of EU subsidiaries. Negotiations are ongoing in regards to preparing finalized agreements between the Company and Mr. Lap’s companies.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS There was no transaction subsequent to the three months ended March 31, 2016.

Summary Of Significant Accoun19

Summary Of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Summary Of Significant Accounting Policies Policies
Organization and General Description of Business	A. Organization and General Description of Business Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS. Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 th th On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders. On November 20, 2014, the Company signed an amendment to the license agreement with Apothecary Genetics Investments LLC. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary. The Company anticipated closing the purchase in fiscal 2015 once all assets are identified with supported fair market values and the transfer of land title is completed.
Basis of Presentation	B. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31. Interim Financial Reporting While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2015 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the three month periods ended March 31, 2016 and 2015. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2015 included in our Form 10-K filed with the SEC on file no. 000-28911 161631274 May 9, 2016. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016. The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the three months ended March 31, 2016: In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany. On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV and MJR BV, both Netherlands registered companies. On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT. On May 6, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. In the state of Tennessee and start the operation of distributing of existing and new line of products. For other accounting policies please refer to the Company’s Form 10-K with the SEC on file no. 000-28911 161631274 May 9, 2016. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have much amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2016
Related Party Transactions Tables
Schedule of Stock Based Compensation with Related Party	For the three months ended March 31, 2016, the following related party stock-based compensation was recorded: Related Party Position Amount Raymond Dabney 1 CEO $ 193,842 Dr. Allen Herman Chief Medical Officer 25,500 Dr. Roscoe M. Moore, Jr Chair of Scientific Advisory Board 151,000 Robert Kane CFO 215,380 Chad S. Johnson, Esq. COO and General Counsel 215,380 Mario Lap 1 Director 215,380 $ 1,016,482

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2016
Equity Transactions Tables
Schedule of Stock Options Outstanding	A summary of the status of the Company’s option grants as of March 31, 2016 and the changes during the period then ended is presented below: Shares Weighted-Average Outstanding December 31, 2015 4,200,000 $ 0.195 Granted 135,000,000 $ 0.010 Exercised 98,500,000 $ 0.010 Expired 2,500,000 $ 0.040 Outstanding March 31, 2016 38,200,000 $ 0.028 Options exercisable at March 31, 2016 38,200,000 $ 0.028
Schedule of Weighted Average Fair Value Assumptions of Stock Option	The weighted average fair value at date of grant for options during year ended March 31, 2016 was estimated using the Black-Scholes option valuation model with the following: Average expected life in years for options with no expiry 2 Years Average expected life in years for options with expiry on 02/22/2017 0.8962 Year Average risk-free interest rate 2.00 % Average volatility 90 % Dividend yield 0 %

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Intangible Assets Tables
Schedule of Goodwill and Intangible Assets	March 31, 2016 December 31, 2015 Intellectual assets, primarily intellectual property and goodwill $ 830,988 $ 830,988 Less accumulated amortization (464,584 ) (445,299 ) Total intangible assets, net $ 366,404 $ 385,689

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended
	Mar. 31, 2016USD ($)
Related Party Transaction [Line Items]
Management fee and stock based compensation	$ 1,016,482
Raymond Dabney - CEO [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	193,842	[1]
Dr. Allen Herman - Cheif Medical Officer [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	25,500
Dr. Roscoe M. Moore, Jr - Chair Of Scientific Advisory Board [Member}
Related Party Transaction [Line Items]
Management fee and stock based compensation	151,000
Robert Kane - CFO [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	215,380
Chad S. Johnson, Esq. - COO And General Counsel [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	215,380
Mario Lap - Director [Member]
Related Party Transaction [Line Items]
Management fee and stock based compensation	$ 215,380	[1]
[1]	Including compensation to entities beneficially owned/control by the related parties

Equity Transactions (Schedule O

Equity Transactions (Schedule Of Stock Options Outstanding) (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Shares
Outstanding December 31, 2015 | shares	4,200,000
Granted | shares	135,000,000
Exercised | shares	98,500,000
Expired | shares	2,500,000
Outstanding March 31, 2016 | shares	38,200,000
Options exercisable at March 31, 2016 | shares	38,200,000
Weighted-Average Exercise Price
Outstanding December 31, 2015 | $ / shares	$ 0.195
Granted | $ / shares	0.010
Exercised | $ / shares	0.010
Expired | $ / shares	0.040
Outstanding March 31, 2016 | $ / shares	0.028
Options exercisable at March 31, 2016 | $ / shares	$ 0.028

Equity Transactions (Schedule25

Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) - Stock Option [Member]	3 Months Ended
	Mar. 31, 2016
Fair value of Stock Options - Black Scholes Options Valuation Model
Average expected life in years for options with no expiry	2 years
Average expected life in years for options with expiry on 02/22/2017	10 months 23 days
Average risk-free interest rate	2.00%
Average volatility	90.00%
Dividend yield	0.00%

Goodwill And Intangible Assets

Goodwill And Intangible Assets (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Total intangible assets, net	$ 204,250	$ 215,000
Intellectual property and Goodwill
Intellecutal assets, primarily intellectual property and goodwill	830,988	830,988
Less accumulated amortization	464,584	445,299
Total intangible assets, net	$ 366,404	$ 385,689

Summary Of Significant Accoun27

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	May. 06, 2015	Feb. 20, 2015	Mar. 31, 2016	Aug. 06, 2014
Business Acquisition [Line Items]
Emerging growth company description			The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have much amount as of December 31, 2015, our last fiscal year.
Asset Acquisition Of Equi-Pharm LLC [Member]
Business Acquisition [Line Items]
Stock issued for purchase of assets, shares	10,000,000
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued for purchase of assets, shares			15,500,000
Michigan Green Technologies, LLC
Business Acquisition [Line Items]
Business acquisition of additional interest acquired percentage				30.10%
Business acquisition total ownership percentage		50.10%
Fair market value of shares issued for business acquisition		$ 60,000
Michigan Green Technologies, LLC | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition, shares issued		1,200,000

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	Nov. 05, 2014	Jul. 25, 2014	Feb. 08, 2013	Dec. 31, 2012	Mar. 07, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Feb. 20, 2015
Related Party Transaction [Line Items]
Advances from related parties						$ 422,080		$ 414,135
Proceeds from related party
Notes payable						$ 1,360,658		1,406,513
Fair value of common stock acquired, value
Equity method investment value						$ 198,362		128,927
Unrealized gain (loss) on marketable securities						$ 69,000	$ (48,750)
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock voting rights						These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.
Michigan Green Technologies, LLC
Related Party Transaction [Line Items]
Business acquisition total ownership percentage									50.10%
Robert Kane - CFO [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties						$ 52,500		$ 52,500
Debt instrument description						A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.		A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.
R Kane Holding Inc - Company Controlled By Robert Kane, CFO [Member]
Related Party Transaction [Line Items]
Advances from related parties						$ 6,000		$ 6,000
Debt instrument description						The debt with no interest and no security.		The debt with no interest and no security.
Proceeds from related party								$ 6,000
R Kane Holding Inc - Company Controlled By Robert Kane, CFO [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties						$ 58,500	$ 0
Proceeds from related party					$ 52,500
R Kane Holding Inc - Company Controlled By Robert Kane, CFO [Member] | Loans Payable [Member] | Michigan Green Technologies, LLC
Related Party Transaction [Line Items]
Business acquisition total ownership percentage					50.10%
Interstate 101 - Shareholder [Member]
Related Party Transaction [Line Items]
Debt instrument description						The debt with no interest and no security.		The debt with no interest and no security.
Notes payable						$ 61,902		$ 61,902
Castor Management Services - Shareholder [Member]
Related Party Transaction [Line Items]
Debt instrument description						The debt with no interest and no security.		The debt with no interest and no security.
Notes payable						$ 3,165		$ 3,165
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] | Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock voting rights		Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters.
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] | Loans Payable [Member]
Related Party Transaction [Line Items]
Advances from related parties						191,344		191,344
MJR BV - Owned By Mario Lap, Director [Member]
Related Party Transaction [Line Items]
Advances from related parties						74,792		66,847
Robert Melamede - Former CEO [Member]
Related Party Transaction [Line Items]
Advances from related parties						$ 447		$ 447
Endocan Corporation Related With Management - Director, CEO, CFO, COO [Member] | Equity Method Investment In Endocan Corporation (EC) [Member]
Related Party Transaction [Line Items]
Common stock invested			2,500,000	5,000,000		7,500,000
Equity method investment ownership percentage						8.60%
Fair value of common stock acquired, value			$ 262,250	$ 150,000
Common stock acquired at fair value			$ 0.1049	$ 0.03
Share value per share						$ 0.015	$ 0.0145	$ 0.015
Equity method investment value						$ 112,500	$ 108,750	$ 112,500
Unrealized gain (loss) on marketable securities	$ 85,862					$ 69,000	(48,750)
Investment in marketable securities	$ 247,500
Impairment of equity method investment								$ 114,000
Endocan Corporation Related With Management - Director, CEO, CFO, COO [Member] | Equity Method Investment In Endocan Corporation (EC) [Member] | Asset Purchase Agreement [Member]
Related Party Transaction [Line Items]
Sale consideration description						The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the Dupetit Natural Products GmbH joint-venture operating agreement to Endocan under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Endocan under an Asset Purchase Agreement.
Common stock shares received on consideration of asset purchase agreement						2,500,000
Embella Holdings Ltd [Member] | Notes Payable [Member]
Related Party Transaction [Line Items]
Notes payable						$ 1,108,896	1,108,896
Intrinsic Capital Corp [Member] | Notes Payable [Member]
Related Party Transaction [Line Items]
Notes payable						$ 231,260	$ 302,088

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details) - USD ($)	Feb. 07, 2016	Mar. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Notes payable to stockholders		$ 1,360,658	$ 1,406,513
Stock issued for debt settlement agreement, value		634,500
Common Stock [Member]
Short-term Debt [Line Items]
Stock issued for debt settlement agreement, value		45,000
Note Payable To Stockholder [Member]
Short-term Debt [Line Items]
Notes payable to stockholders		$ 1,360,658	$ 1,406,513
Debt instrument description		The notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through February 7, 2014. The Promissory notes were in default on March 31, 2016. All promissory notes are unsecured.	The notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through February 7, 2014. The Promissory notes were in default on March 31, 2016. All promissory notes are unsecured.
Notes Payable [Member] | Common Stock [Member] | Stacey R. Lewis, Stockholder [Member]
Short-term Debt [Line Items]
Stock issued for debt settlement agreement, value	$ 634,500

Equity Transactions (Narrative)

Equity Transactions (Narrative) (Details) - USD ($)	Mar. 22, 2016	Mar. 22, 2016	Mar. 08, 2016	Feb. 29, 2016	Feb. 22, 2016	Feb. 07, 2016	Feb. 01, 2016	Sep. 16, 2011	Mar. 31, 2016	Mar. 31, 2015
Shares issued for services during the period, value									$ 775,368
Original debt converted									45,855	$ 180,828
Loss on settlement of debt									$ (588,645)	$ (2,358,076)
Stock issued for property license agreement, value
Common stock issued for stock option exercised, shares									98,500,000
Common stock issued for stock option exercised, value									$ 629,550
Exercise price of stock options									$ 0.010
Stock Option [Member]
Common stock issued for stock option exercised, shares					25,000,000
Common stock issued for stock option exercised, value					$ 307,500
Description of stock option expiration									1,700,00 shares of these options at an exercise price of $0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane and 36,500,000 shares at an exercise price of $0.01 a share expires on February 22, 2017.
V.P Of Investor Relations, CFO And Director For Services [Member] | Stock Option [Member]
Share based compensation description								The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement: (i) the option to purchase 100,000 common shares at ten cents ($0.10) per share; (ii) the option to purchase 100,000 common shares at twenty cents ($0.20) per share; (iii) the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and (iv) the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.
Management Agreement With Consulting Firm [Member]
Management agreement terms							On February 1, 2016, the Company entered a management agreement with a consulting firm and agreed to issue 15,000,000 shares of R144 restricted common stock with a fair market value of $180,000 for investor relation services.
Common Class A [Member]
Common stock voting rights									These shares have 10 votes per share.
Series A Preferred Stock [Member]
Preferred stock voting rights									These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.
Common Shares
Common stock voting rights									These shares have full voting rights.
Total shares issued during the period									103,000,000
Shares issued for service during the period, shares									103,000,000
Shares issued for services during the period, value									$ 103,000
Stock issued for debt settlement agreement, shares									45,000,000
Common stock issued for stock option exercised, shares									98,500,000
Common stock issued for stock option exercised, value									$ 98,500
Common Shares | Scientific Advisory Board Agreement Of The 2016 Equity Plan [Member]
Shares issued for service during the period, shares		10,000,000
Shares issued for services during the period, value		$ 151,000
Common Shares | 2016 Equity Award Plan [Member]
Common stock issued for stock option exercised, shares	5,000,000
Common stock issued for stock option exercised, value	$ 75,500
Exercise price of stock options	$ 0.01
Common Shares | Stacey R. Lewis, Stockholder [Member] | Notes Payable [Member]
Original debt converted						$ 45,855
Original debt carrying amount						$ 75,044
Stock issued for debt settlement agreement, shares						45,000,000
Loss on settlement of debt						$ (588,645)
Common Shares | Consultant - Management Agreement [Member] | 2015 Equity Award Plan [Member]
Common stock issued for stock option exercised, shares					7,000,000
Common stock issued for stock option exercised, value					$ 86,100
Exercise price of stock options					$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2015 Equity Award Plan [Member]
Common stock issued for stock option exercised, shares					6,500,000
Common stock issued for stock option exercised, value					$ 79,950
Exercise price of stock options					$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2016 Equity Award Plan [Member]
Common stock issued for stock option exercised, shares				25,000,000
Common stock issued for stock option exercised, value				$ 300,000
Exercise price of stock options				$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2015 Equity Plan [Member]
Common stock issued for stock option exercised, shares	15,000,000
Common stock issued for stock option exercised, value	$ 226,500
Exercise price of stock options	$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2016 Equity Plan [Member]
Common stock issued for stock option exercised, shares	5,000,000
Common stock issued for stock option exercised, value	$ 75,500
Exercise price of stock options	$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2016 Equity Plan [Member]
Common stock issued for stock option exercised, shares	10,000,000
Common stock issued for stock option exercised, value	$ 151,000
Exercise price of stock options	$ 0.01
Common Shares | Consultant - Management Agreement [Member] | 2016 Equity Plan [Member]
Common stock issued for stock option exercised, shares	15,000,000
Common stock issued for stock option exercised, value	$ 226,500
Exercise price of stock options	$ 0.01
Rule 144 Restricted Stock [Member] | Chad S. Johnson, COO/General Legal Counsel - Management Agreement [Member]
Shares issued for service during the period, shares			20,000,000
Shares issued for services during the period, value			$ 215,380
Rule 144 Restricted Stock [Member] | Raymond Dabney - CEO [Member]
Shares issued for service during the period, shares			18,000,000
Shares issued for services during the period, value			$ 193,842
Rule 144 Restricted Stock [Member] | MJR BV - Owned By Mario Lap, Director [Member]
Shares issued for service during the period, shares			20,000,000
Shares issued for services during the period, value			$ 215,380
Rule 144 Restricted Stock [Member] | Robert Kane - CFO [Member]
Shares issued for service during the period, shares			20,000,000
Shares issued for services during the period, value			$ 215,380

Property Farming License (Narra

Property Farming License (Narrative) (Details) - USD ($)	Mar. 24, 2016	Mar. 31, 2016
Property license for cultivation		$ 25,000
Joint Venture License Agreement With Ft. McDermitt Allotment Land Allotees [Member]
Joint venture license agreement terms	The Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made an initial payment of $25,000 for licensing and initial development of the first one (1) acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.
Property license for cultivation	$ 25,000

Deposits (Narrative) (Details)

Deposits (Narrative) (Details) - USD ($)	Jan. 11, 2016	Nov. 20, 2014	Feb. 09, 2012	Mar. 31, 2016	Dec. 31, 2015
Share-based Goods and Nonemployee Services Transaction [Line Items]
Deposits related to acquisition				$ 1,152,850	$ 971,500
Acquisition Of Apothecary Genetics Investments [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Deposits related to acquisition				$ 181,350
Rule 144 Restricted Stock [Member] | Acquisition Of Apothecary Genetics Investments [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
License agreement terms and amendment	Pursuant to the second amendment the Company waives prior Royalties owed under any Section of any previous Agreements, and Apothecary shall make business introductions in Jamaica for the Company to work with government licensed growers, laboratories, doctors, and any other mutually agreeable business introductions. Apothecary will immediately sign and transfer ownership of the Northern California Property to the Company and repay and discharge a lien on the property within 12 months signing the second amendment.
Shares issued for acquisition of property, building and equipment	15,500,000	14,500,000
Shares issued for license agreement, value	$ 181,350	$ 971,500
Licensing Agreements With Apothecary [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
License agreement terms and amendment		Apothecary failed to meet several contract provisions including investing $250,000 in R&D, setting up a laboratory facility, and reporting and remitting license fees owing to the Company. On November 20, 2014, the Company signed an amendment to the license agreement. Pursuant to the amendment, the Company is acquiring all property, building, and equipment of Apothecary	Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding in addition to investing $250,000 in research and development in the first 24 months.

Equity Method Investee (Narrati

Equity Method Investee (Narrative) (Details) - USD ($)	Nov. 05, 2014	Mar. 31, 2016	Mar. 31, 2015
Schedule of Equity Method Investments [Line Items]
Unrealized gain (loss) on marketable securities		$ 69,000	$ (48,750)
Endocan Corporation Related With Management - Director, CEO, CFO, COO [Member] | Equity Method Investment In Endocan Corporation (EC) [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment description	This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.
Unrealized gain (loss) on marketable securities	$ 85,862	$ 69,000	$ (48,750)

Goodwill And Intangible Asset34

Goodwill And Intangible Assets (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset useful life	5 years
Intellectual Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset useful life	5 years